Record Nr.	UNINA9910300300803321
Titolo	Antimicrobial Resistance in the 21st Century / / edited by I. W. Fong, David Shlaes, Karl Drlica
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018
ISBN	3-319-78538-9
Edizione	[2nd ed. 2018.]
Descrizione fisica	1 online resource (773 pages)
Collana	Emerging Infectious Diseases of the 21st Century
Disciplina	616.90461
Soggetti	Immunology
	Infectious diseases
	Microbiology
	Fpidemiology
	Public health
	Infectious Diseases
	Public Health
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Chapter1: Introduction : Coordinated Global Action is Needed to Combat Antimicrobial Resistance Part I: Examples of Resistance Chapter2: Antimicrobial Resistance Among Streptococcus pneumoniae Chapter3: Emergence of MRSA in the Community Chapter4: Resistance of Gram-negative Bacilli to Antimicrobials Chapter5: Drug Resistance in Tuberculosis Chapter6: Anaerobic Bacteria: Antimicrobial Susceptibility Testing and Resistance Patterns Chapter7: Clinical Significance and Biologic Basis of HIV Drug Resistance Chapter8: Resistance of Herpesviruses to Antiviral Agents Chapter9: Heteroresistance: A Harbinger of Future Resistance Part II: Biology of Resistance Chapter10: Epidemiology of Bacterial Resistance Chapter11: Transmissible Antibiotic Resistance Chapter12: Antibiotics and Resistance in the Environment Chapter13: Phenotypic Tolerance and Bacterial Persistence Chapter14: Staphylococcus aureus Adaptation During Infection

1.

	Chapter15: Bacterial Signal Transduction Systems in Antimicrobial Resistance Chapter16: Fluoroquinolone Interactions with Bacterial Type II Topoisomerases and Target-mediated Drug Resistance Part III: Finding New Antimicrobials Chapter17: Natural Products in Antibiotic Discovery Chapter18: The New vs. Old Target Debate For Drug Discovery Chapter19: Non-quinolone Topoisomerase Inhibitors Chapter20: Antimicrobial-Mediated Bacterial Suicide Chapter21: PK/PD-based Prediction of "Anti-mutant" Antibiotic Exposures Using In Vitro Dynamic Models Part IV: Bringing Compounds to Market Chapter22: The Role of Pharmacometrics in the Development of Antimicrobial Agents Chapter23: New Regulatory Pathways for Antibacterial Drugs Chapter24: Economic Incentives for Antibacterial Drug Development: Alternative Market Structures to Promote Innovation.
Sommario/riassunto	Antimicrobial resistance is now a general problem. Many of us have elderly relatives who died from a drug-resistant infection, and some of us have suffered from a resistant urinary infection that likely came from intestinal bacteria following antibiotic consumption. Antimicrobial Resistance in the 21st Century provides a broad introduction to the subject in which the situation with problematic pathogens is detailed, the biology of resistance is described, and gaining approval for new antibiotics is discussed. Some topics are immediately practical, such as watching for resistant pathogen sub-populations in cultures taken from patients; other topics point to future research efforts that may lead to new antimicrobial Resistance in the 21st Century provides an update for physicians, serves as a starting point for graduate students interested in solving the resistance problem, and may serve as a text for a course on resistance. Lay readers familiar with microbiology will gain an appreciation for a medical issue that promises to be one of the most important of our time. Ignatius Fong, Department of Medicine, University of Toronto Series Editor – Emerging Infectious Diseases of the 21st Century David Shlaes, Founder, Anti-Infectives Consulting Editor – Antimicrobial Agents and Chemotherapy Karl Drlica, The Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey.